Does Ravulizumab Interact with Efgartigimod Alfa?
Ravulizumab and Efgartigimod Alfa have a moderate drug interaction according to U.S. FDA drug labeling data. Neonatal Fc receptor blocker that may lower systemic exposures and reduce effectiveness of ULTOMIRIS; closely monitor for reduced effectiveness. The mechanism involves lowers systemic exposures of ravulizumab. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Ravulizumab Class
- Complement Inhibitor
- Efgartigimod Alfa Class
- Neonatal Fc Receptor Blocker
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Ravulizumab and Efgartigimod Alfa occurs because lowers systemic exposures of ravulizumab. Clinically, this means neonatal fc receptor blocker that may lower systemic exposures and reduce effectiveness of ultomiris; closely monitor for reduced effectiveness. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Ravulizumab and your doctor is considering prescribing Efgartigimod Alfa (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider